Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research (CDER), will retire from the agency in July 2025124.
Corrigan-Curay stepped into the acting CDER director role in January 2025 after the previous director, Patrizia Cavazzoni, left shortly before President Donald Trump’s second term began25.
Her departure is part of a recent wave of high-profile exits at the FDA, following reports that other top officials—including Nicole Verdun, director of the cell and gene therapy office, and her deputy Rachael Anatol—were relieved of their duties recently25.
Corrigan-Curay has spent nearly a decade at the FDA, previously serving as director of CDER’s Office of Medical Policy and as principal deputy director for CDER5.
In an email to staff, Corrigan-Curay described her decision to retire as ‘incredibly challenging’ and plans to remain for several weeks to assist with the leadership transition125.
Sources:
1. https://www.statnews.com/2025/06/23/fda-cder-acting-director-jacqueline-corrigan-curay-retiring-departures-mount/
2. https://www.fiercepharma.com/pharma/fdas-acting-cder-head-corrigan-curay-heads-exit-amid-period-heavy-turnover-reports
4. https://www.biopharmadive.com/news/fda-jacqueline-corrigan-curay-retire-exit-cder/751337/
5. https://www.biospace.com/fda/acting-cder-head-becomes-latest-in-string-of-fda-leaders-to-leave-agency